Search
Now showing items 1-5 of 5
Cognitive dysfunction studied in animal models of schizophrenia
(2006-12-01)
Cognitive dysfunction is considered a core deficit of schizophrenia, which currently lacks effective pharmacological treatment. In order to identify novel and more effective drug treatments, translational experimental ...
Schizophrenia and nitric oxide. Deficits in information processing investigated in animal models
(2004)
Rationale: Schizophrenia-like symptoms can be induced in humans by phencyclidine (PCP), a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor. Schizophrenic patients and PCP-treated animals display ...
Cognition and social behaviour in schizophrenia: An animal model investigating the potential role of nitric oxide
(2007-11-27)
Cognitive deficits are the single strongest predictor of functional outcome in patients with schizophrenia. Furthermore, these deficits are not satisfactorily alleviated by available antipsychotic treatment. Functional ...
Dopaminergic stabilizers for the treatment of schizophrenia. Rat studies focusing on negative symptoms and mechanisms of action
(2007-11-21)
Schizophrenia is a severe mental disorder manifested by positive, negative and cognitive symptoms. Current antipsychotic drugs have poor effects on negative and cognitive symptoms, thus necessitating the development of new ...
Cognitive dysfunction studied in animal models of schizophrenia
(2006)
Cognitive dysfunction is considered a core deficit of schizophrenia, which currently lacks effective pharmacological treatment. In order to identify novel and more effective drug treatments, translational experimental ...